Tuniu (TOUR) Inks Half-Billion Investment; CTI BioPharma (CTIC) Biotech Forward Momentum


Shares of Tuniu Corp. (Nasdaq:TOUR) are surging in pre-market trading Monday after the company said that HNA Tourism Group will invest $500 million in Tuniu by buying TOUR stock for about $16.50 per ADS. The deal also calls for an strategic partnership between the companies

Tuniu expects to release its third quarter 2015 financial results after the closing bell today.

TOUR stock closed at $15.71, up $0.18 (or +1.16%) on Friday’s market activity

Tuniu, a leading online leisure travel company in China, has 93.34M Shares Outstanding, Market Capitalization (intraday) of $1.47B and TOUR stock 52-week range is $10.33 – $20.85 per share



CTI BioPharma Corp. (Nasdaq:CTIC) said before the opening bell on Monday that a combination of its pacritinib with an epidermal growth factor receptor (EGFR) Inhibitor may improve clinical outcomes for patients with Glioblastoma Multiforme, the most aggressive of the gliomas, by targeting brain tumor initiating cells

CTIC stock finished the last trading session at $1.10, down $0.01 (or -0.90%)

CTI BioPharma, a biopharmaceutical company, has 231.72M Shares Outstanding, Market Capitalization (intraday) of $254.90M and CTIC stock one-year range is between $1.07 and $2.94 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/